Efficacy and safety of fixed-combination brimonidine tartrate/timolol maleate in primary open-angle glaucoma, including normal-tension glaucoma
- 문서 유형
- 연구출판물 · 학술지 논문
- 등재
- SCIEScopus
- 저널 순위
- JCR Q3Scopus Q2
- 저널
- JAPANESE JOURNAL OF OPHTHALMOLOGY65(2) · pp.295 · 2021
- 피인용
- Web of Science 2Scopus 4
- FWCI (Scopus)
- 0.33
- JCR IF
- JCR 2020 2.447
- ISSN
- 0021-5155
저자
- Park, Sang Woo제1저자Chonnam National University Hospital, Chonnam National University Medical School, Gwangju, Korea
- Kim, Joon MoDepartment of Ophthalmology, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea
- 이지웅Pusan National University Hospital, Pusan National University School of Medicine, Busan, Korea
- Maglambayan, JoyMedical Affairs, Allergan (an AbbVie company), Singapore, Singapore
- Simonyi, SusanMedical Affairs, Allergan (an AbbVie company), Singapore, Singapore
- Park, Ki Ho교신저자Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea
초록
Purpose To assess the 12-month efficacy and safety of fixed-combination brimonidine tartrate 0.2%/timolol maleate 0.5% (FCBT) with or without bimatoprost 0.01% (BIM) in primary open-angle glaucoma (POAG), including normal-tension glaucoma (NTG). Study design Prospective, multicenter, open-label study. Methods FCBT was self-administered twice daily after applicable washout (study eye). Intraocular pressure (IOP) was measured at baseline and months 1, 3, 6, 9, and 12. BIM could be added for IOP >= 21 mmHg, IOP reduction from baseline < 20%, or the investigator deemed it necessary. Primary endpoint: mean (11-a.m.) month-12 IOP change from baseline. Secondary endpoints included mean IOP changes from baseline at other visits, median time to achieving and patients (%) achieving target IOP reduction with FCBT, and visual field (VF) progression rate over 12 months. Safety was assessed at each visit. Results Of 118 eyes with POAG (NTG, n = 93), 87 used FCBT; 31 required FCBT + BIM. Mean IOP changes from baseline (16.8 and 15.3 mmHg) to month 12 were - 4.1 mmHg (FCBT, n = 62) and - 3.5 mmHg (FCBT + BIM, n = 15), respectively (both P < 0.0001). Patients who achieved target IOP reduction with FCBT did so in 1 month (median). VF progression rates were 0.17%/year (FCBT, P = 0.8367) and - 0.08%/year (FCBT + BIM, P = 0.9410). Ocular treatment-emergent adverse events occurred in 42.5% (FCBT) and 71.0% (FCBT + BIM) of patients; most were mild and included ocular hyperemia (9.2% and 41.9%, respectively). Conclusions Despite low mean baseline IOP, >= 20% IOP reduction from baseline persisted over 12 months with FCBT and FCBT + BIM, without clinically significant VF progression. Tolerability was consistent with reported drug safety profiles.
키워드
BimatoprostBrimonidine tartrateLow-tension glaucomaTimololHyperemia
식별자
- Scopus EID
- 2-s2.0-85100893825
- WoS UID
- 000618575500001



로그인
연구물 목록으로